Clinical Trials Logo
  1. Home
  2. Covid19
  3. NCT04366024
  4. Details
NCT04366024 Clinical Trial

A Novel Nomogram to Predict Severity of COVID-19

COVID-19 Disease Clinical Trial

Official title:
A Novel Nomogram to Predict Severity of COVID-19

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT04366024
Other study ID # XQonc-016
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 17, 2020
Est. completion date December 31, 2021

Study information
Verified date February 2024
Source Xinqiao Hospital of Chongqing
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Investigators use clinical data from a large sample of COVID-19 disease patients to screen out biomarkers associated with disease severity. Then, a novel nomogram model will be established to predict covid-19 disease severity, which could provide important assistance and supplement for clinical work. In the case of extremely shortage of front-line medical resources, patients with potential severe diseases will be timely treated with the help of the novel nomogram model.

Recruitment information / eligibility
Status Completed
Enrollment 1000
Est. completion date December 31, 2021
Est. primary completion date August 30, 2020
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - COVID-19 disease patients confirmed by virus nucleic acid RT-PCR and CT Exclusion Criteria: - unconfirmed suspected cases - Patients during pregnancy and lactation - incomplete clinical data - investigators considered patients ineligible for the trial - Child patients

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• other
clinical diagnosis

Locations
Country Name City State
China Xinqiao Hospital of Chongqing Chongqing Chongqing

Sponsors (1)
Lead Sponsor Collaborator
Xinqiao Hospital of Chongqing

Country where clinical trial is conducted

China, 

Outcome
Type Measure Description Time frame Safety issue
Primary the consistency of predicted severe rate and observed severe rate of COVID-19 patients We aim to use the clinical data of COVID-19 patients to construct a nomogram model to predict the severe rate of each patient, then the the consistency of predicted severe rate and observed severe rate will be evaluated by calibration plot. up to 3 months
Primary Duration of severe illness the duration of severe illness of each patient will evaluated up to 3 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04984408 - Efficacy, Immunogenicity and Safety of BBIBP-CorV Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. Phase 3
Terminated NCT04642638 - Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure Phase 2/Phase 3
Recruiting NCT04587323 - VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease
Completed NCT04682873 - A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus Phase 3
Completed NCT04359212 - Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19
Completed NCT05603130 - Epidemiologic Register on Diabetes and COVID-19 in Tunisia
Completed NCT04830800 - A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC Phase 1/Phase 2
Completed NCT04757792 - Back to the Traditional: Anti-COX Drugs Can Improve the Outcome of COVID-19 Patients Admitted to ICU
Active, not recruiting NCT04417257 - Study of LAU-7b for the Treatment of COVID-19 Disease in Adults Phase 2/Phase 3
Recruiting NCT04522037 - Measurement of the Efficacy of MORPHINE in the Early Management of Dyspnea in COVID-19 Positive Patients
Completed NCT04446377 - A Study of LAM-002A for the Prevention of Progression of COVID-19 Phase 2
Active, not recruiting NCT04969172 - A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Exosomes Overexpressing CD24 to Prevent Clinical Deterioration in Patients With Moderate or Severe COVID-19 Infection Phase 2
Completed NCT04347369 - A Retrospective Study of Neural Network Model to Dynamically Quantificate the Severity in COVID-19 Disease
Completed NCT04787510 - COVID-19 Disease and Coagulopathy: Assessment of Clotting Factor Levels in Patients With SARS-CoV-2 Infection
Completed NCT05329220 - ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 Phase 3
Active, not recruiting NCT05077267 - ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects Phase 2
Completed NCT04472013 - Systematic Assessment of SARS-CoV-2 Neurotropic Capacity in Modestly and Critically Ill Patients, and Patients Who Died From COVID-19
Active, not recruiting NCT04371354 - Outcomes of Covid-19 Protective Measures in Endoscopy
Not yet recruiting NCT04779359 - Role of Lymphocyte Subsets and Laboratory Measurements in COVID-19 Disease